论文部分内容阅读
目的探讨曲美他嗪联合麝香保心丸治疗稳定型心绞痛的临床疗效。方法选取2014年1月—2016年2月吉安市中心人民医院就诊的稳定型心绞痛患者80例,随机分为对照组与治疗组,各40例。对照组给予常规药物治疗(包括阿司匹林、硝酸异山梨酯片、酒石酸美托洛尔片、阿托伐他汀钙片、马来酸依那普利片),治疗组在对照组基础上给予曲美他嗪联合麝香保心丸治疗。比较两组患者每次跑步机上活动耐量、ST段压低数值、临床疗效及不良反应发生率。结果治疗前两组患者每次跑步机上活动耐量及ST段压低数值比较,差异无统计学意义(P>0.05);治疗后治疗组每次跑步机上活动耐量高于对照组,ST段压低数值低于对照组,差异有统计学意义(P<0.05)。治疗组总有效率高于对照组,心电图检查表现恢复正常时间短于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论曲美他嗪联合麝香保心丸治疗稳定型心绞痛的临床疗效确切,可有效改善患者症状,且不良反应少。
Objective To investigate the clinical efficacy of trimetazidine combined with Shexiang Baoxin Pill in the treatment of stable angina pectoris. Methods From January 2014 to February 2016, 80 patients with stable angina pectoris who were treated in Ji’an Central People’s Hospital were randomly divided into control group and treatment group, 40 cases in each group. The control group was given conventional drug therapy (including aspirin, isosorbide dinitrate tablets, metoprolol tartrate tablets, atorvastatin calcium tablets, enalapril maleate tablets), the treatment group on the basis of the control group to Qu Mei Hezine combined with musk heart pill treatment. The treadmill exercise tolerance, ST-segment depression, clinical efficacy and incidence of adverse reactions were compared between the two groups. Results There was no significant difference in activity tolerance and ST-segment depression between treadmill before and after treatment in each group (P> 0.05). After treatment, the activity of each treadmill in treatment group was higher than that in control group. The value of ST depression was low In the control group, the difference was statistically significant (P <0.05). The total effective rate in the treatment group was higher than that in the control group, and the electrocardiogram examination showed a shorter recovery time than the control group (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Trimetazidine combined with Shexiang Baoxin Pill has definite curative effect in the treatment of stable angina pectoris, which can effectively improve the symptoms of patients with less adverse reactions.